Relafen 750, pharmacologically known as naproxen, represents a important case study from a pharmacological pharmacy standpoint. It's exhibits its therapeutic effect primarily by blocking the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin formation. The selective inhibition of COX-2, compared to traditio